ASPARLAS (calaspargase pegol)

ASPARLAS (calaspargase pegol)

OFFICE ADMINISTRATION-IV 

Indications for Prior Authorization:

• Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) in pediatric and young adults aged 1 month to 21 years

Patients must meet the following criteria for the indication(s) above:

• 1 month to 21 years of age, AND
• Diagnosis of acute lymphoblastic leukemia confirmed by an oncologist or hematologist

Contraindications:

• History of serious hypersensitivity reactions to pegylated L-asparaginase
• History of serious thrombosis during L-asparaginase therapy
• History of serious pancreatitis related to previous L-asparaginase treatment
• History of serious hemorrhagic events during previous L-asparaginase treatment
• Severe hepatic impairment

Precautions:

• Use in specific populations:
  • Breast-feeding considerations: not recommended by the manufacturer during therapy and for 3 months after the last Asparlas dose

Dosing:

• 2500 units/m² (as part of a combination chemotherapy regimen)
• Not administered more frequently than every 21 days

Approval:

• 1 year